ThermoGenesis Holdings, Inc. (NASDAQ:THMO) Q3 2020 Earnings Conference Call November 12, 2020  4:30 PM ET
Company Participants
Paula Schwartz - Managing Director, Rx Communications
Chris Xu - CEO
Jeff Cauble - CFO
Conference Call Participants
Sean Lee - H.C. Wainwright
Operator
Good day and welcome to ThermoGenesis Holdings Conference Call and Webcast to review the financial and operating results for the third quarter ended September 30, 2020. [Operator Instructions] As a reminder this call is being recorded.
I would now like to turn the conference over to our host, Paula Schwartz, Rx Communications. Please go ahead.
Paula Schwartz
Thank you, Operator. This conference call contains forward-looking statements within the meaning of the federal securities laws. The company's actual results may differ materially from those projected in the forward-looking statements. Additional information concerning factors that might cause actual results to differ materially from those in the forward-looking statements is contained in the company's periodic reports filed with the Securities and Exchange Commission. The information presented today is time-sensitive and is accurate only as of the date of this call, November 12, 2020. If any portion of this call is being rebroadcast, retransmitted or redistributed at a later date ThermoGenesis will not be reviewing or updating this material.
Participating on today's call are Dr. Chris Xu, Chief Executive Officer; and Jeff Cauble, Chief Financial Officer.
I'd now like to turn the call over to Chris. Please go ahead, Chris.
Chris Xu
Thank you, Paula, and thank you to everyone for joining the call this afternoon. We appreciate you taking the time this evening.
During the third quarter of 2020 as COVID 19 cases continue to escalate worldwide, we continue to evaluate our strategies to cope with the global pandemic. Meanwhile, we continue to serve our global customers in the cell gene therapy field by providing them with the cutting edge tools to meet with their cell processing needs.
As a reminder for the past 20 years, the company's core business competence resides in its leadership and ability to develop cutting-edge tools and systems for the cell processing in the cell gene therapy field and our products include the CAR-TXpress platform based on the latest highly innovative buoyancy activated cell sorting technology.
So the BACS technology is our patent protected high efficiency cell sorting technology using lipid micro-bubbles instead of the traditional magnetic beads activated cell sorting or MACS. The BACS technology is the key component of the CAR-TXpress platform, which is intended to address the critical unmet need for large-scale cellular manufacturing for the cell-based therapies.
The CAR-TXpress system itself is a multi-modular base system that offers customers a streamless solution for cell processing, selection, washing, reformulation and query preservation. Providing a comprehensive and commercial viable cell manufacturing solution for CAR-T, CAR-NK and other cell-based therapeutics.
Two, the AXP, BioArchive platform, which is a leading automated cell processing and smart cloud storage platform for clinical biobanking. The AXP system represents a significant advancement in the automated cord blood processing allowing for fast automated and high quality stem cell enrichment from cord blood. The BioArchive system is the industrials leading smart query preservation system providing the ultimate performance and protection for today's high valued cells for tomorrow's critical therapy needs.
And three, our PXP platform for point-of-care applications which allows for rapid and automated processing of autologous cells from peripheral blood or bone marrow at the point of care which are such as surgical centers or clinics. It also allows isolation offer different cell fractions from the blood simultaneously.